Corpus overview


MeSH Disease

Syndrome (6)

Fever (5)

Cough (5)

Infections (4)

Asthma (3)

Human Phenotype


    displaying 1 - 9 records in total 9
    records per page

    Fighting COVID-19 spread among nursing home residents even in absence of molecular diagnosis: a retrospective cohort study.

    Authors: Alessio Strazzulla; Paul Tarteret; Maria Concetta Postorino; Marie Picque; Astrid de Pontfarcy; Nicolas Vignier; Catherine Chakvetadze; Coralie Noel; Cecile Drouin; Zine Eddine Benguerdi; Sylvain Diamantis

    doi:10.21203/ Date: 2020-07-30 Source: ResearchSquare

    Background Access to molecular diagnosis was limited out-of-hospital in France during the 2020 coronavirus disease MESHD 2019 (COVID-19) epidemic. This study describes the evolution of COVID-19 outbreak in a nursing home in absence of molecular diagnosis. Methods A monocentric prospective study was conducted in a French nursing home from March 17th, 2020 to June 11th, 2020. Because of lack of molecular tests for severe acute respiratory syndrome MESHD 2 (SARS-Cov2) infection MESHD, probable COVID-19 cases were early identified considering only respiratory and not-respiratory symptoms and therefore preventing measures and treatments were enforced. Once available, serology tests were performed at the end of the study.A chronologic description of new cases and deaths MESHD was made together with a description of COVID-19 symptoms. Data about personal characteristics and treatments were collected and the following comparisons were performed: i) probable COVID-19 cases vs asymptomatic TRANS residents; ii) SARS-Cov2 seropositive residents vs seronegative residents. Results Overall, 32/66 (48.5%) residents and 19/39 (48.7%) members of health-care personnel were classified as probable COVID-19 cases. A total of 34/61 (55.7%) tested residents resulted seropositive. Death MESHD occurred in 4/66 (6%) residents. Diagnosis according to symptoms had 65% of sensitivity SERO, 78% of specificity, 79% of positive predictive value SERO and 64% of negative predictive value SERO.In resident population, the following symptoms were registered: 15/32 (46.8%) lymphopenia MESHD lymphopenia HP, 15/32 (46.8%) fever MESHD fever HP, 8/32 (25%) fatigue MESHD fatigue HP, 8/32 (25%) cough MESHD cough HP, 6/32 (18.8%) diarrhoea, 4/32 (12.5%) severe respiratory distress HP requiring oxygen therapy, 4/32 (12.5%) fall HP, 3/32 (9.4%) conjunctivitis MESHD conjunctivitis HP, 2/32 (6.3%) abnormal pulmonary noise at chest examination and 2/32 (6,25%) abdominal pain MESHD abdominal pain HP. Probable COVID-19 cases were older (81.3 vs 74.9; p=0.007) and they had higher prevalence SERO of atrial fibrillation MESHD atrial fibrillation HP (8/32, 25% vs 2/34, 12%; p=0.030); insulin treatment (4/34, 12% vs 0, 0%; p=0.033) and positive SARS-Cov2 serology (22/32, 69% vs 12/34, 35%; p=0.001) than asymptomatic TRANS residents. Seropositive residents had lower prevalence SERO of diabetes (4/34, 12% vs 9/27, 33%; p=0.041) and angiotensin-converting-enzyme inhibitors’ intake (1/34, 1% vs 5/27, 19%; p=0.042). Conclusions During SARS-Cov2 epidemic, early detection of respiratory and not-respiratory symptoms allowed to enforce extraordinary measures. They achieved limiting contagion and deaths MESHD among nursing home residents, even in absence of molecular diagnosis.

    Critical Complications of COVID-19: A systematic Review and Meta-Analysis study

    Authors: Kimia Vakili; Mobina Fathi; Fatemeh Sayehmiri; Ashraf Mohamadkhani; Mohammadreza Hajiesmaeili; Mostafa Rezaei-Tavirani; Aiyoub Pezeshgi

    doi:10.1101/2020.06.14.20130955 Date: 2020-06-16 Source: medRxiv

    Background: Coronavirus disease MESHD 2019 (COVID-19) is a novel coronavirus infection MESHD that has spread worldwide in a short period and caused a pandemic. The goal of this meta-analysis is to evaluate the prevalence SERO of most common symptoms and complications of COVID-19. Methods: All related studies assessing the clinical complications of COVID-19 have been identified through web search databases (PubMed and Scopus). Relevant data were extracted from these studies and analyzed by stata (ver 14) random-effects model. The heterogeneity of studies were assessed by I2 index. The publication bias was examined by Funnel plots and Eggers test. Results: 30 studies were in our meta-analysis including 6 389 infected patients. The prevalence SERO of most common symptoms were: fever MESHD fever HP 84.30% (95% CI: 77.13-90.37; I2=97.74%), cough MESHD cough HP 63.01% (95% CI: 57.63-68.23; I2=93.73%), dyspnea MESHD dyspnea HP 37.16% (95% CI: 27.31-47.57%; I2=98.32%), fatigue MESHD fatigue HP 34.22% (95% CI: 26.29-42.62; I2=97.29%) and diarrhea MESHD diarrhea HP 11.47 %(95% CI: 6.96-16.87; I2=95.58%), respectively. The most prevalent complications were acute respiratory distress HP syndrome MESHD (ARDS) 33.15% (95% CI: 23.35-43.73; I2=98.56%), acute cardiac injury 13.77% (95% CI: 9.66-18.45; I2=91.36%), arrhythmia HP 16.64% (95% CI: 9.34-25.5; I2=92.29%), heart failure MESHD 11.50% (95% CI: 3.45-22.83; I2=89.48%), and acute kidney injury MESHD acute kidney injury HP (AKI) 8.40 %(95% CI: 5.15-12.31; I2=95.22%, respectively. According to our analysis, mortality rate of COVID-19 patients were 12.29% (95% CI: 6.20-19.99; I2=98.29%). Conclusion: We assessed the prevalence SERO of the main clinical complications of COVID-19 and found that after respiratory complications, cardiac and renal complications are the most common clinical complications of COVID-19.

    Prevalence SERO and mortality of Lung Comorbidities Among Patients with COVID-19: A systematic review and meta-analysis

    Authors: Mohammed G Alkhathami; Shailesh Advani; Adil A Abalkhail; Fahad M Alkhathami; Mohammed K AlShehri; Ebtisam Albeashy; Jihad A Al Salamah

    doi:10.1101/2020.06.01.20119271 Date: 2020-06-03 Source: medRxiv

    Abstract Background COVID-19 infections MESHD are seen across all age groups TRANS but they have shown to have a predisposition for the elderly TRANS and those with underlying comorbidities. Patients with severe COVID-19 infections MESHD and comorbidities are more prone to respiratory distress HP syndrome MESHD (ARDS), mechanical ventilator use and ultimately succumb to these complications. Little evidence exists of the prevalence SERO of underlying lung comorbidities among COVID-19 patients and associated mortality. Methods We performed a systematic review of the literature including PubMed (Medline), Embase (Ovid), Google Scholar and Cochrane Library. The last date for our search was 29th April 2020. We included all original research articles on COVID-19 and calculated prevalence SERO of chronic lung disease HP lung disease MESHD patients among COVID-19 patients using random effects model. Further we assessed for mortality rates among COVID-19 patients associated with these lung comorbidities. Results The authors identified 29 articles that reported prevalence SERO of chronic lung conditions among COVID-19 patients. Among those, 26 were from China and 3 from the United States. The pooled prevalence SERO of lung comorbidities including Asthma MESHD Asthma HP, COPD, and lung cancer was 3% (95% CI=0-14%), 2.2% (95% CI=0.02-0.03%) and 2.1% (95% CI=0.00-0.21%) respectively. Mortality rates associated with these comorbidities was 30% (41/137) for COPD and 19% (7/37) for lung cancer respectively. No mortality rates were reported for patients with asthma MESHD asthma HP. Conclusion This study offers latest evidence of prevalence SERO of chronic lung conditions among patients with COVID-19. Asthma MESHD Asthma HP, followed by COPD and lung cancer, was the most common lung comorbidity associated with COVID-19, while the higher mortality rate was found in COPD. Future studies are needed to assess other lung comorbidities and associated mortality among patients diagnosed with COVID-19.

    Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Network.

    Authors: José Manuel Casas Rojo; Juan Miguel Antón Santos; Jesús Millán Núñez-Cortés; Carlos Lumbreras Bermejo; José Manuel Ramos Rincón; Emilia Roy-Vallejo; Arturo Artero Mora; Francisco Arnalich Fernández; José Miguel García Bruñén; Juan Antonio Vargas Núñez; Santiago J Freire Castro; Luis Manzano; Isabel Perales Fraile; Anxela Crestelo Vieitez; Francesc Puchades; Enrique Rodilla; Marta Nataya Solís Marquínez; David Bonet Tur; María del Pilar Fidalgo Moreno; Eva M Fonseca Aizpuru; Franscisco Javier Carrasco Sánchez; Elisa Rabadán Pejenaute; Manuel Rubio-Rivas; José David Torres Peńa; Ricardo Gómez Huelgas

    doi:10.1101/2020.05.24.20111971 Date: 2020-05-26 Source: medRxiv

    Background. Spain has been one of the countries most affected by the COVID-19 pandemic. Objective. To create a registry of patients with COVID-19 hospitalized in Spain in order to improve our knowledge of the clinical, diagnostic, therapeutic, and prognostic aspects of this disease MESHD. Methods. A multicentre retrospective cohort study, including consecutive patients hospitalized with confirmed COVID-19 throughout Spain. Epidemiological and clinical data, additional tests at admission and at seven days, treatments administered, and progress at 30 days of hospitalization were collected from electronic medical records. Results. Up to April 30th 2020, 6,424 patients from 109 hospitals were included. Their median age TRANS was 69.1 years (range: 18-102 years) and 56.9% were male TRANS. Prevalences SERO of hypertension MESHD hypertension HP, dyslipidemia, and diabetes mellitus MESHD diabetes mellitus HP were 50.2%, 39.7%, and 18.7%, respectively. The most frequent symptoms were fever MESHD fever HP (86.2%) and cough MESHD cough HP (76.5%). High values of ferritin (72.4%), lactate dehydrogenase (70.2%), and D-dimer (61.5%), as well as lymphopenia MESHD lymphopenia HP (52.6%), were frequent. The most used antiviral drugs were hydroxychloroquine (85.7%) and lopinavir/ritonavir (62.4%). 31.5% developed respiratory distress HP. Overall mortality rate was 21.1%, with a marked increase with age TRANS (50-59 years: 4.2%, 60-69 years: 9.1%, 70-79 years: 21.4%, 80-89 years: 42.5%, [≥] 90 years: 51.1%). Conclusions. The SEMI-COVID-19 Network provides data on the clinical characteristics of patients with COVID-19 hospitalized in Spain. Patients with COVID-19 hospitalized in Spain are mostly severe cases, as one in three patients developed respiratory distress HP and one in five patients died. These findings confirm a close relationship between advanced age TRANS and mortality.

    Vitamin D deficiency MESHD in critically ill patients diagnosed with COVID -19. Are we doing enough? A retrospective analysis of 226 patients.

    Authors: Tomás Cuñat; Antonio Ojeda; Andrea Calvo

    doi:10.21203/ Date: 2020-05-19 Source: ResearchSquare

    Vitamin D deficiency MESHD is common in critically ill patients, and its role in COVID-19 patients could be important. Its deficiency has been associated with respiratory distress HP syndrome MESHD, pulmonary fibrosis MESHD pulmonary fibrosis HP (through activation of the renin-angiotensin system), increased levels of IL-2, and cardiovascular adverse events. Various scientific societies recommend the screening of vitamin D in individuals at risk for deficiency. Despite that, the demographics of Vitamin D levels amongst critically ill patients with a confirmed diagnosis of COVID-19 are currently unknown. We propose a study to determine the prevalence SERO of vitamin D deficiency MESHD in a consecutive population of COVID-19 patients admitted to intensive care units and to evaluate its relationship with clinical outcomes. We study 226 COVID-19 patients between March 16 and April 26, 2020. The prevalence SERO of vitamin D deficiency MESHD could not be determined because the value of 25-hydroxyvitamin D was obtained in a few patients (17 patients, 7,5%). However, all patients with serum SERO determinations of 25-hydroxyvitamin D presented a level lower than 20 ng/ml and thirteen patients (76,5%) levels < 12,5 ng/ml. We conclude that undiagnosed vitamin D deficiency MESHD is common in critically ill COVID-19 patients, and physicians should be conscious of the relevance of its monitoring and supplementation.

    Clinical features of 162 fatal cases of COVID-19: a multi-center, retrospective study

    Authors: Xianlong Zhou; Guoyong Ding; Qing Fang; Jun Guo; Luyu Yang; Ping Wang; Shouzhi Fu; Ang Li; Jian Xia; Jiangtao Yu; Jianyou Xia; Min Ma; Zhuanzhuan Hu; Lei Huang; Ruining Liu; Cheng Jiang; Shaoping Li; Mingxia Yu; Xizhu Xu; Yan Zhao; Quan Hu; Weijia Xing; Zhigang Zhao

    doi:10.21203/ Date: 2020-05-15 Source: ResearchSquare

    Understanding the epidemiological and clinical characteristics of fatal cases infected with SARS-CoV-2 is import to develop appropriate preventable intervention programs in hospitals. Demographic data, clinical symptoms, clinical course, co-morbidities, laboratory findings, CT scans, treatments and complications of 162 fatal cases were retrieved from electric medical records in 5 hospitals of Wuhan, China. The median age TRANS was 69.5 years old (IQR: 63.0-77.25; range: 29-96). 112 (69.1%) cases were men. Hypertension MESHD Hypertension HP (45.1%) was the most common co-morbidity, but 59 (36.4%) cases had no co-morbidity. At admission, 131 (81.9%) cases were assessed as severe or critical. However, 39 (18.1%) were assessed as moderate. Moderate cases had a higher prevalence SERO of hypertension MESHD hypertension HP and chronic lung disease HP lung disease MESHD comparing with severe or critical cases (P<0.05, respectively). 126 (77.8%) and 132 (81.5%) cases received antiviral treatment and glucocorticoids, respectively. 116 (71.6%) cases were admitted to ICU and 137 (85.1%) cases received mechanical ventilation. Respiratory failure HP or acute respiratory distress HP syndrome MESHD (93.2%) was the most common complication. The young cases of COVID-19, without co-morbidity and in a moderate condition at admission could develop fatal outcome. We need to be more cautious in case management of COVID-19 for preventing the fatal outcomes.

    Identification of pulmonary comorbid diseases MESHD network based repurposing effective drugs for COVID-19

    Authors: Jai Chand Patel; Rajkumar Tulswani; Pankaj Khurana; Yogendra Kumar Sharma; Lilly Ganju; Bhuvnesh Kumar; Ragumani Sugadev

    doi:10.21203/ Date: 2020-05-08 Source: ResearchSquare

    The number of hospitalization of COVID-19 patients with one or more comorbid diseases MESHD is highly alarming. Despite the lack of large clinical data and incomplete understanding of virus pathology, identification of the COVID-19 associated diseases MESHD with clinical precision are highly limited. In this regard, our text mining of 6238 PubMed abstracts (as on 23 April 2020) successfully identified broad spectrum of COVID-19 comorbid diseases MESHD/disorders (54), and their prevalence SERO on the basis of the number of occurrence of disease MESHD terms in the abstracts. The disease MESHD ontology based semantic similarity network analysis revealed the six highly comorbid diseases MESHD of COVID-19 namely Viral Pneumonia MESHD Pneumonia HP, Pulmonary Fibrosis MESHD Pulmonary Fibrosis HP, Pulmonary Edema MESHD Pulmonary Edema HP, Acute Respiratory Distress HP Syndrome MESHD (ARDS), Chronic Obstructive Pulmonary Disease MESHD Chronic Obstructive Pulmonary Disease HP (COPD) and Asthma MESHD Asthma HP. The disease MESHD gene bipartite network revealed 15 genes that were strongly associated with several viral pathways including the corona viruses may involve in the manifestation (mild to critical) of COVID-19. Our tripartite network- based repurposing of the approved drugs in the world market revealed six promising drugs namely resveratrol, dexamethasone, acetyl cysteine, Tretinoin, simvastatin and aspirin to treat comorbid symptoms of COVID-19 patients. Our animal studies in rats and literatures strongly supported that resveratrol is the most promising drug to possibly reduce several comorbid symptoms associated with COVID-19 including the severe hypoxemia HP induced vascular leakage. Overall, the anti-viral properties of resveratrol against corona virus could be readily exploited to effectively control the viral load at early stage of COVID-19 infection MESHD through nasal administration.

    The Utility of rRT-PCR in Diagnosis and Assessment of Case-fatality rates of COVID-19 In the Iranian Population. Positive Test Results are a Marker for Illness Severity

    Authors: Ghasem Janbabaei; Eric J. Brandt; Reza Golpira; Alireza Raeisi; Jafar Sadegh Tabrizi; Hamid Reza Safikhani; Mohammad Taghi Talebian; Siamak Mirab Samiee; Alireza Biglar; Reza Malekzadeh; Arya Mani

    doi:10.1101/2020.04.29.20085233 Date: 2020-05-05 Source: medRxiv

    The utility of PCR-based testing in characterizing patients with COVID-19 and the severity of their disease MESHD remains unknown. We performed an observational study among patients presenting to hospitals in Iran who were tested for 2019-nCoV viral RNA by rRT-PCR between the fourth week of February 2020 to the fourth week of March 2020. Frequency of symptoms, comorbidities, intubation, and mortality rates were compared between COVID-19 positive vs. negative patients. 96103 patients were tested from 879 hospitals. 18754 (19.5%) tested positive for COVID-19. Positive testing was more frequent in those 50 years or older. The prevalence SERO of cough MESHD cough HP (54.5% vs. 49.7%), fever MESHD fever HP (49.5% vs. 44.7%), and respiratory distress HP (43.0% vs. 39.0%) but not hypoxia MESHD (46.9% vs. 56.7%) was higher in COVID-19 positive vs. negative patients (p<0.001 for all). More patients had cardiovascular diseases MESHD (10.6% vs. 9.5%, p<0.001) and type 2 diabetes mellitus MESHD diabetes mellitus HP (10.8% vs. 8.7%, p<0.001) among COVID-19 positive vs. negative patients. There were fewer patients with cancer (1.1%, vs. 1.4%, p<0.001), asthma MESHD asthma HP (1.9% vs. 2.5%, p<0.001), or pregnant (0.4% vs. 0.6%, =0.001) in COVID-19 positive vs. negative groups. COVID-19 positive vs. negative patients required more intubation (7.7% vs. 5.2%, p<0.001) and had higher mortality (14.6% vs. 6.3%, p<0.001). Odds ratios for death MESHD of positive vs negative patients range from 2.01 to 3.10 across all age groups TRANS. In conclusion, COVID-19 test-positive vs. test-negative patients had more severe symptoms and comorbidities, required higher intubation, and had higher mortality. rRT-PCR positive result provided diagnosis and a marker of disease MESHD severity in Iranians.

    Clinical, Laboratory and Imaging Features of COVID-19: A Systematic Review and Meta-analysis

    Authors: Alfonso J. Rodriguez-Morales; Jaime A. Cardona-Ospina; Estefanía Gutiérrez-Ocampo; Rhuvi Villamizar-Peña; Yeimer Holguin-Rivera; Juan Pablo Escalera-Antezana; Lucia Elena Alvarado-Arnez; D. Katterine Bonilla-Aldana; Carlos Franco-Paredes; Andrés F. Henao-Martinez; Alberto Paniz-Mondolfi; Guillermo J. Lagos-Grisales; Eduardo Ramírez-Vallejo; Jose A. Suárez; Lysien I. Zambrano; Wilmer E. Villamil-Gómez; Graciela J. Balbin-Ramon; Ali A. Rabaan; Harapan Harapan; Kuldeep Dhama; Hiroshi Nishiura; Hiromitsu Kataoka; Tauseef Ahmad; Ranjit Sah

    id:10.20944/preprints202002.0378.v3 Date: 2020-03-11 Source:

    Introduction: An epidemic of Coronavirus Disease MESHD 2019 (COVID-19) begun in December 2019 in China, causing a Public Health Emergency MESHD of International Concern. Among raised questions, clinical, laboratory, and imaging features have been partially characterized in some observational studies. No systematic reviews have been published on this matter. Methods: We performed a systematic literature review with meta-analysis, using three databases to assess clinical, laboratory, imaging features, and outcomes of COVID-19 confirmed cases TRANS. Observational studies, and also case reports, were included and analyzed separately. We performed a random-effects model meta-analysis to calculate the pooled prevalence SERO and 95% confidence interval (95%CI). Results: 660 articles were retrieved (1/1/2020-2/23/2020). After screening by abstract/title, 27 articles were selected for full-text assessment. Of them, 19 were finally included for qualitative and quantitative analyses. Additionally, 39 case report articles were included and analyzed separately. For 656 patients, fever MESHD fever HP (88.7%, 95%CI 84.5-92.9%), cough MESHD cough HP (57.6%, 40.8-74.4%) and dyspnea MESHD dyspnea HP (45.6%, 10.9-80.4%) were the most prevalent manifestations. Among the patients, 20.3% (95%CI 10.0-30.6%) required intensive care unit (ICU), with 32.8% presenting acute respiratory distress HP syndrome MESHD (ARDS) (95%CI 13.7-51.8), 6.2% (95%CI 3.1-9.3) with shock MESHD shock HP and 13.9% (95%CI 6.2-21.5%) of hospitalized patients with fatal outcomes (case fatality rate, CFR).Conclusion: COVID-19 brings a huge burden to healthcare facilities, especially in patients with comorbidities. ICU was required for approximately 20% of polymorbid, COVID-19 infected patients and this group was associated with a CFR of over 13%. As this virus spreads globally, countries need to urgently prepare human resources, infrastructure, and facilities to treat severe COVID-19.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.